Angiotensin receptor blockers are associated with reduced fibrosis and interleukin-6 expression in calcific aortic valve disease

Pathobiology

Volumn 81, Issue 1, 2013, Pages 15-24

  Côté, Nancy ^a   Mahmut, Ablajan ^a   Fournier, Dominique ^a   Boulanger, Marie Chloé ^a   Couture, Christian ^b   Després, Jean Pierre ^b   Trahan, Sylvain ^b   Bossé, Yohan ^b   Pagé, Sylvain ^b   Pibarot, Philippe ^b   Mathieu, Patrick ^a  

^a Groupe de Recherche en Valvulopathies   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

Angiotensin receptor blockers; Aortic stenosis; Calcific aortic valve disease; Fibrosis; Inflammation; Interleukin 6; Small dense low density lipoproteins

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INTERLEUKIN 6; APOLIPOPROTEIN B; CALCIUM; COLLAGEN; CREATININE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 1BETA; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

AGED; AORTA VALVE DISEASE; ARTICLE; CALCIFICAORTIC VALVE DISEASE; CARDIOMETABOLIC RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ECHOCARDIOGRAPHY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATION; INFLAMMATORY CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SCORING SYSTEM; VASCULAR FIBROSIS; AORTA STENOSIS; AORTA VALVE; AORTA VALVE FIBROSIS; AORTA VALVE REPLACEMENT; BICUSPID AORTIC VALVE; CALCIFIC AORTIC VALVE DISEASE; CELL INFILTRATION; FIBROSIS; HEART HEMODYNAMICS; QUANTITATIVE ANALYSIS; TREATMENT DURATION;

AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; AORTIC VALVE; CALCINOSIS; FEMALE; FIBROSIS; HEART DEFECTS, CONGENITAL; HEART VALVE DISEASES; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-6; MALE; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84884703844     PISSN: 10152008     EISSN: 14230291     Source Type: Journal    
DOI: 10.1159/000350896     Document Type: Article

References (21)

1. Rajamannan NM, Evans FJ, Aikawa E, Grande- Allen KJ, Demer LL, Heistad DD, Simmons CA, Masters KS, Mathieu P, O'Brien KD, Schoen FJ, Towler DA, Yoganathan AP, Otto CM: Calcific aortic valve disease: not simply a degenerative process. A review and agenda for research from the National Heart and Lung and Blood Institute Aortic Stenosis Working Group. Executive summary: calcific aortic valve disease - 2011 update. Circulation 2011; 124: 1783-1791.
2. Stewart BF, Siscovick D, Lind BK, Gardin JM, Gottdiener JS, Smith VE, Kitzman DW, Otto CM: Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol 1997; 29: 630-634. (Pubitemid 27116107)
3. Mathieu P, Despres JP, Pibarot P: The 'valvulometabolic' risk in calcific aortic valve disease. Can J Cardiol 2007; 23(suppl B):32B-39B. (Pubitemid 47629138)
4. Mathieu P, Poirier P, Pibarot P, Lemieux I, Despres JP: Visceral obesity: the link among inflammation, hypertension, and cardiovascular disease. Hypertension 2009; 53: 577-584.
5. Mathieu P, Lemieux I, Despres JP: Obesity, inflammation, and cardiovascular risk. Clin Pharmacol Ther 2010; 87: 407-416.
6. Cote C, Pibarot P, Despres JP, Mohty D, Cartier A, Arsenault BJ, Couture C, Mathieu P: Association between circulating oxidised low-density lipoprotein and fibrocalcific remodelling of the aortic valve in aortic stenosis. Heart 2008; 94: 1175-1180.
7. O'Brien KD, Shavelle DM, Caulfield MT, McDonald TO, Olin-Lewis K, Otto CM, Probstfield JL: Association of angiotensinconverting enzyme with low-density lipoprotein in aortic valvular lesions and in human plasma. Circulation 2002; 106: 2224- 2230. (Pubitemid 35222217)
8. Helske S, Lindstedt KA, Laine M, Mayranpaa M, Werkkala K, Lommi J, Turto H, Kupari M, Kovanen PT: Induction of local angiotensin II-producing systems in stenotic aortic valves. J Am Coll Cardiol 2004; 44: 1859-1866. (Pubitemid 39424087)
9. Ma F, Li Y, Jia L, Han Y, Cheng J, Li H, Qi Y, Du J: Macrophage- stimulated cardiac fibroblast production of IL-6 is essential for TGFß/Smad activation and cardiac fibrosis induced by angiotensin II. PLoS One 2012; 7:e35144.
10. Zhang W, Wang W, Yu H, Zhang Y, Dai Y, Ning C, Tao L, Sun H, Kellems RE, Blackburn MR, Xia Y: Interleukin 6 underlies angiotensin II-induced hypertension and chronic renal damage. Hypertension 2012; 59: 136-144.
11. Mohty D, Pibarot P, Despres JP, Cote C, Arsenault B, Cartier A, Cosnay P, Couture C, Mathieu P: Association between plasma LDL particle size, valvular accumulation of oxidized LDL, and inflammation in patients with aortic stenosis. Arterioscler Thromb Vasc Biol 2008; 28: 187-193.
12. Mathieu P, Pibarot P, Larose E, Poirier P, Marette A, Despres JP: Visceral obesity and the heart. Int J Biochem Cell Biol 2008; 40: 821- 836.
13. Briand M, Lemieux I, Dumesnil JG, Mathieu P, Cartier A, Despres JP, Arsenault M, Couet J, Pibarot P: Metabolic syndrome negatively influences disease progression and prognosis in aortic stenosis. J Am Coll Cardiol 2006; 47: 2229-2236. (Pubitemid 43795081)
14. Katz R, Wong ND, Kronmal R, Takasu J, Shavelle DM, Probstfield JL, Bertoni AG, Budoff MJ, O'Brien KD: Features of the metabolic syndrome and diabetes mellitus as predictors of aortic valve calcification in the Multi- Ethnic Study of Atherosclerosis. Circulation 2006; 113: 2113-2119.
15. Despres JP, Lemieux I, Bergeron J, Pibarot P, Mathieu P, Larose E, Rodes-Cabau J, Bertrand OF, Poirier P: Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol 2008; 28: 1039-1049.
16. Cote N, Pibarot P, Pepin A, Fournier D, Audet A, Arsenault B, Couture C, Poirier P, Despres JP, Mathieu P: Oxidized low-density lipoprotein, angiotensin II and increased waist circumference are associated with valve inflammation in prehypertensive patients with aortic stenosis. Int J Cardiol 2010; 145: 444-449.
17. Bosse Y, Miqdad A, Fournier D, Pepin A, Pibarot P, Mathieu P: Refining molecular pathways leading to calcific aortic valve stenosis by studying gene expression profile of normal and calcified stenotic human aortic valves. Circ Cardiovasc Genet 2009; 2: 489-498.
18. Cote N, Couture C, Pibarot P, Despres JP, Mathieu P: Angiotensin receptor blockers are associated with a lower remodelling score of stenotic aortic valves. Eur J Clin Invest 2011; 41: 1172-1179.
19. O'Brien KD, Probstfield JL, Caulfield MT, Nasir K, Takasu J, Shavelle DM, Wu AH, Zhao XQ, Budoff MJ: Angiotensin-converting enzyme inhibitors and change in aortic valve calcium. Arch Intern Med 2005; 165: 858-862. (Pubitemid 40563231)
20. Rosenhek R, Rader F, Loho N, Gabriel H, Heger M, Klaar U, Schemper M, Binder T, Maurer G, Baumgartner H: Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis. Circulation 2004; 110: 1291-1295. (Pubitemid 39202347)
21. Arishiro K, Hoshiga M, Negoro N, Jin D, Takai S, Miyazaki M, Ishihara T, Hanafusa T: Angiotensin receptor-1 blocker inhibits atherosclerotic changes and endothelial disruption of the aortic valve in hypercholesterolemic rabbits. J Am Coll Cardiol 2007; 49: 1482-1489. (Pubitemid 46482919)